UPDATE 1-Lilly's breast cancer drug combination succeeds key study

March 20 (Reuters) - Eli Lilly and Co said a combination of its experimental breast cancer drug and another widely used treatment slowed disease progression in a key study in patients who had relapsed or did not derive enough benefit from anti-estrogen therapy.